350 related articles for article (PubMed ID: 9383433)
1. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming.
Gehlhaar DK; Verkhivker GM; Rejto PA; Sherman CJ; Fogel DB; Fogel LJ; Freer ST
Chem Biol; 1995 May; 2(5):317-24. PubMed ID: 9383433
[TBL] [Abstract][Full Text] [Related]
2. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
3. A method for biomolecular structural recognition and docking allowing conformational flexibility.
Sandak B; Nussinov R; Wolfson HJ
J Comput Biol; 1998; 5(4):631-54. PubMed ID: 10072081
[TBL] [Abstract][Full Text] [Related]
4. Fragment-Based flexible ligand docking by evolutionary optimization.
Budin N; Majeux N; Caflisch A
Biol Chem; 2001 Sep; 382(9):1365-72. PubMed ID: 11688719
[TBL] [Abstract][Full Text] [Related]
5. Efficient molecular docking of NMR structures: application to HIV-1 protease.
Huang SY; Zou X
Protein Sci; 2007 Jan; 16(1):43-51. PubMed ID: 17123961
[TBL] [Abstract][Full Text] [Related]
6. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
Radhika V; Jaraf HA; Kanth SS; Vijjulatha M
Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770
[TBL] [Abstract][Full Text] [Related]
7. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
8. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
Prashar V; Bihani SC; Ferrer JL; Hosur MV
Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
[TBL] [Abstract][Full Text] [Related]
10. Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead.
Perez MA; Fernandes PA; Ramos MJ
J Mol Graph Model; 2007 Oct; 26(3):634-42. PubMed ID: 17459746
[TBL] [Abstract][Full Text] [Related]
11. Development, validation, and applications of anisotropic polarizable molecular mechanics to study ligand and drug-receptor interactions.
Gresh N
Curr Pharm Des; 2006; 12(17):2121-58. PubMed ID: 16796560
[TBL] [Abstract][Full Text] [Related]
12. Conformational analysis of TMC114, a novel HIV-1 protease inhibitor.
Nivesanond K; Peeters A; Lamoen D; Van Alsenoy C
J Chem Inf Model; 2008 Jan; 48(1):99-108. PubMed ID: 18173253
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
14. Exploring the energy landscapes of molecular recognition by a genetic algorithm: analysis of the requirements for robust docking of HIV-1 protease and FKBP-12 complexes.
Verkhivker GM; Rejto PA; Gehlhaar DK; Freer ST
Proteins; 1996 Jul; 25(3):342-53. PubMed ID: 8844869
[TBL] [Abstract][Full Text] [Related]
15. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
16. Interdependence of Inhibitor Recognition in HIV-1 Protease.
Paulsen JL; Leidner F; Ragland DA; Kurt Yilmaz N; Schiffer CA
J Chem Theory Comput; 2017 May; 13(5):2300-2309. PubMed ID: 28358514
[TBL] [Abstract][Full Text] [Related]
17. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
[TBL] [Abstract][Full Text] [Related]
18. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.
Ode H; Ota M; Neya S; Hata M; Sugiura W; Hoshino T
J Phys Chem B; 2005 Jan; 109(1):565-74. PubMed ID: 16851048
[TBL] [Abstract][Full Text] [Related]
19. Predicting structural effects in HIV-1 protease mutant complexes with flexible ligand docking and protein side-chain optimization.
Schaffer L; Verkhivker GM
Proteins; 1998 Nov; 33(2):295-310. PubMed ID: 9779795
[TBL] [Abstract][Full Text] [Related]
20. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
Ghosh AK; Gemma S; Baldridge A; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
J Med Chem; 2008 Oct; 51(19):6021-33. PubMed ID: 18783203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
